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Abstract
Background. The survival of hemodialysis patients requiring dialysis depends on the long-term functioning and patency of the
vascular access. Prosthetic vascular grafts are inevitably used for patients whose vessels are unsuitable for an autogenous
arteriovenous (AV) ﬁstula. The purpose of this study was to compare the patency rate and associated complications using
different types of grafts.
Methods. This prospective study was conducted on patients who did not have an appropriate vein for arteriovenous ﬁstula from
January 2004 through July 2006. They were divided into two groups, sex, age, and basic data matched. Polytetraﬂuoroethylene
(PTFE) and polyurethane (PVAG) were the two types of grafts used in this study. The functionality of the graft was assessed
immediately 1 day and 2 weeks after operation. The clinical follow-up was performed each 3 months until 24 months.
Results. One-year patency rate was reported to be 64% and 52% in the PTFE and PVAG groups, respectively. There was no
signiﬁcant difference in 1-year (64% versus 52%) and 2-year (49% versus 41%) patency rate of the PTFE and PVAG grafts
used as vascular access. There was also no difference between the numbers of complications reported in the two groups.
Conclusion. It could be concluded that either PTFE or PVAG grafts can be used with the same expected outcomes.
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Introduction
The number of patients requiring dialysis for end
stage renal disease is increasing rapidly. The pro-
longed survival of this group of patients depends on
the long-term functioning and patency of the vascular
access for hemodialysis (1). Prosthetic vascular grafts
are inevitably used for patients whose vessels are
unsuitable for an autogenous arteriovenous (AV)
ﬁstula due to several reasons, especially diabetes
mellitus-derived atherosclerosis (2).
The artiﬁcial polytetraﬂuoroethylene (PTFE) graft
was ﬁrst developed in 1969 by Robert W. Gore and in
1976, Campell et al. had the ﬁrst successful experi-
ence on human beings. PTFE grafts have been widely
used as artiﬁcial grafts in vascular surgery; its
expanded form has been reported to have acceptable
outcomes (3–6).
Different reports have shown low infection rates,
being patent for the short and the long term, and not
requiring pre-clotting as the advantages of PTFE over
older types (such as Dacron) (3,7). The greater need
fortemporarycathetersinindividualsreceivingPTFEs,
however,increasesnotonlythecostsbutalsotheriskof
infection, bleeding, and poor blood ﬂow (8).
On the other hand, neointimal hyperplasia and
distal arteriosclerosis are the most important compli-
cations following the administration of these types of
grafts (9,10).
Attempts to discover a complication-free graft has
led to the invention of the polyurethane vascular
access graft (PVAG) (11). Several reports have
demonstrated self-sealing properties, low risk of
neointimal hyperplasia and coagulability using this
graft. Moreover, they can be cannulated within
2 days of placement, avoiding the need for temporary
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compare the patency rate and associated complica-
tions using different types of grafts.
Material and method
The study was performed as a prospective study from
January 2004 through July 2006. Fifty patients in need
of a vascular access for the ﬁrst time, who did not have
an appropriate vein for arteriovenous ﬁstula, were
enrolled inthestudy. Cases whichdeveloped thrombo-
sis, infection, and other complications, such as venous
hypertensionandstealsyndrome,inwhichremovingthe
graft was obligatory, were classiﬁed as failure.
They were divided into two groups, sex, age, and
basic data matched based on the randomized alloca-
tion software. A total of 12 females and 13 males
participated in each group. The location of the vas-
cular graft, the technique of the surgery, the length of
the graft, the stitch string used, the length of arterio-
venous anastomosis, and the procedures carried out
pre- and post-operation were the same in the two
groups. Two surgeons performed an equal number of
operations in each group. The patients received 1 g
cephazolin intravenous (IV) half an hour prior to the
operation as prophylaxis. All the grafts were located
on the non-dominant arm. Grafts were washed with
normal saline solution and 10,000 units of heparin.
Grafts were located subcutaneously so that the arterial
anastomosis to the brachial artery and the venous
anastomosis to the axillary vein would be near the
elbow. End-to-side 8 mm arterial and 12 mm venous
anastomosis was performed with prolene 6.0.
Two types of grafts, all 20 cm in length and 8 mm
in diameter, were used during this study: 1) polyte-
traﬂuoroethylene (PTFE), standard wall manu-
factured by Gore Co., Flagstaff, AZ, USA; and 2)
polyurethane (PVAG) manufactured by Vasculink
Co., Woburn, UK.
The functionality of the graft was assessed imme-
diately 1 day and 2 weeks after the operation. The
clinical follow-up was performed each 3 months until
24 months. Examination in each session was carried
out via touching the thrill, auscultating the bruit, and
assessing the outcome of the performed hemodialysis.
The follow-up was performed for 2 years, and the
failedcasesandalsothesurvivaltimeofeachcasewere
recorded. The subjects who died or underwent trans-
plantationduringthestudyperiodwerecensoredfrom
the study, and those in need of graft removal due to
thrombosis and infection were considered as failure.
The gathered data were entered in SPSS v. 13 and
analyzed using Kaplan-Meier and t test. Continuous
variables were expressed as mean and standard
deviation.
Results
There was no signiﬁcant difference between the age
and the gender of the patients studied in the two
groups (Table I). The difference in the numbers of
diabetics in the two groups was not statistically sig-
niﬁcant (Table II).
The mean arterial diameters in the PTFE and
PVAG groups were 4 and 4.2 mm, respectively; the
corresponding mean venous diameters were 6.33 and
9.4 mm.
The 1-year patency rates were 64% and 52% in the
PTFE and PVAG groups, respectively. The 2-year
patency rates were 49% and 41%, correspondingly.
ThemeansurvivalratesofthepatientsreceivingPTFE
andPVAGinthesametimeperiodwere16±2(ranging
between13and20)and14±2(rangingbetween10and
18) months. No signiﬁcant difference was reported in
these groups (P-value = 0.35).
From the 50 patients enrolled in the study, 4 (8%)
expired, and 2 (4%) underwent transplantation dur-
ing the study period. Table III shows the number of
Table I. The demographic data of the studied patients in the two groups.
PTFE (n = 50) PVAG (n = 50) P-value
Sex
Male 24 29 0.212
Female 26 21
Age (yrs) 57.64 ± 13.3 61.06 ±12.29 0.185
Previous dialysis duration
(yrs)
3.96 ± 1.76 3.90 ± 1.80 0.866
Mean arterial blood
pressure (MAP) (mmHg)
4 4.2 0.506
Venous diameter (mm) 6.33 9.4 0.002
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occurred in 5 and 6 cases of PTFE and PVAG,
respectively. A signiﬁcant difference was not found
between these two groups (P-value = 0.77).
Infection, steal syndrome (diagnosed based on
clinical symptoms including pallor, diminished pulse
(distal to the ﬁstula), necrosis, decreased wrist-
brachial index (ratio of blood pressure measured in
the wrist and that of the upper arm), and pain distal to
the ﬁstula), and venous hypertension were the most
common complications. There was no signiﬁcant
difference between the numbers of cases experiencing
complications during the study period in the two
groups.
Discussion
Due to signiﬁcant increase in the number of patients
in need of hemodialysis, the use of vascular grafts in
those without a suitable vein for arteriovenous ﬁstula
has increased signiﬁcantly. The long-term survival of
these patients, hence, depends on the appropriate
function of these vascular accesses.
Nowadays, polytetraﬂuoroethylene (PTFE) and
polyurethane (PVAG) are among the most frequently
used vascular grafts in the world (1,6,11). Several
studies have reported different complications and
patency rates for these artiﬁcial grafts. Some studies
have shown new PVAG grafts to be better than the
PTFE ones in terms of early access and prompt
hemostasis; however, others have questioned the
long-term patency and safety of PVAG grafts (13–17).
In a study performed in Australia, PVAG was used
in 92% of the procedures in which vascular access was
required in an emergency setting. According to this
study, a problem-free (primary) and functional (sec-
ondary) patency was reported in 44.9% and 64.5% of
the patients, respectively. It was concluded that
PVAG is the graft of choice in patients requiring
an urgent, reliable, medium- to long-term hemodi-
alysis access (18). On the contrary, other studies have
shown PTFE to be an efﬁcient vascular access for
hemodialysiswhere aprimaryﬁstulaorbrachio-basilic
transplantation is not possible (6,17,19). Modarai
et al., however, reported a poor patency rate and a
high risk of complication (infection and thrombosis)
using this graft (20). A study conducted in 2005
showed that the temporary catheters used in PTFE
grafts increase not only the costs but also the risk of
infection, bleeding, and poor blood ﬂow. It also
showed decreased bleeding time, risk of infection,
and anemia exacerbation with PVAG grafts (21). Sim-
ilarly, Nakagawa et al. reported several advantages of
PVAGoverPTFE.Theseadvantagesincludedprompt
hemostasis and sufﬁcient mechanical strength along
with the absence of persistent edema, seroma forma-
tion,andanychangeintheelasticity(22).Ontheother
hand, Matsuda et al. experienced few thromboses
using PTFE. Primary patency rate was also reported
to be signiﬁcantly better in the group with PTFE;
however, there was no considerable difference in the
secondarypatencyrateofthetwografts(19).Glickman
et al., conversely, demonstrated the PVAG grafts to
have similar patency and efﬁcacy when compared with
the PTFE grafts in dialysis patients. They, however,
stressed that PVAG can be cannulated early without
increasingtheinfectionrateorsacriﬁcingpatency(23).
Contrary to the majority of the above-mentioned
studies, our prospective study revealed no signiﬁcant
difference in 1- and 2-year patency or in the frequency
of the complications between the two grafts, indicat-
ing that either PTFE or PVAG grafts can be used with
Table II. The prevalence of the underlying diseases leading to
dialysis requirement in the studied patients.
PTFE (n = 50) PVAG (n = 50)
Diabetes mellitus 35 31
Renal diseases 25 26
Hypertension 28 37
Tobacco use 28 34
Obesity 17 19
Other 4 2
Table III. The number of censored and failed cases.
PTFE (%) PVAG (%) P-value 95% CI
Censored
Transplant 2 (8) - 0.038 0.0954–0.31046
Death 2 (8) 2 (8) 1.000 0.21279–0.21279
Failure
Thrombosis 3 (12) 5 (20) 1.000 0.24789–0.24789
Infection 2 (8) 1 (4) 0.646 0.13374–0.21374
PTFE grafts compared with polyurethane grafts 247the same expected outcomes in hemodialysis patients
in need of a vascular access. Further studies with
larger sample sizes, however, are needed to conﬁrm
the results of this study.
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